Onconova Therapeutics, Inc. (ONTX)
Dopo ore:
| Chiusura precedente | 0,7582 |
| Aperto | 0,7870 |
| Denaro | 0,7150 x 1100 |
| Lettera | 0,7156 x 1000 |
| Min-Max giorno | 0,7120 - 0,7898 |
| Intervallo di 52 settimane | 0,6200 - 1,9300 |
| Volume | |
| Media Volume | 218.454 |
| Capitalizzazione | 15,291M |
| Beta (5 anni mensile) | 1,81 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,1450 |
| Prossima data utili | 09 mag 2023 - 15 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 6,33 |
- GlobeNewswire
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
Collaboration builds off clinical data demonstrating rigosertib’s activity against PLK1 and may inform a precision medicine approach towards rigosertib’s evaluation in new indications Collaboration will leverage ENLIGHT, a pan-cancer response predictor scalable to all cancer types and all targeted and immune checkpoint blockade (ICB) oncology drugs NEWTOWN, Pa. & TEL AVIV, Israel, March 23, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopha
- GlobeNewswire
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET todayNEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended December 31, 2022, and provided a business update. Highlights for the fourth quarter of 2022 and recent weeks include: Based upon encouraging safety findin
- GlobeNewswire
Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting
NEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2
